[go: up one dir, main page]

DK0946731T3 - Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser - Google Patents

Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser

Info

Publication number
DK0946731T3
DK0946731T3 DK97950245T DK97950245T DK0946731T3 DK 0946731 T3 DK0946731 T3 DK 0946731T3 DK 97950245 T DK97950245 T DK 97950245T DK 97950245 T DK97950245 T DK 97950245T DK 0946731 T3 DK0946731 T3 DK 0946731T3
Authority
DK
Denmark
Prior art keywords
strain
hiv
ybf30
regard
group
Prior art date
Application number
DK97950245T
Other languages
English (en)
Inventor
Ibtissam Loussert-Ajaka
Philippe Mauclere
Francois Simon
Sentob Saragosti
Francoise Barre-Sinoussi
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK0946731T3 publication Critical patent/DK0946731T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
DK97950245T 1996-12-09 1997-12-08 Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser DK0946731T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615087A FR2756843B1 (fr) 1996-12-09 1996-12-09 Souches de vih-1 non-m non-o, fragments et applications
PCT/FR1997/002227 WO1998026075A1 (fr) 1996-12-09 1997-12-08 Souches de vih-1 non-m non-o, fragments et applications

Publications (1)

Publication Number Publication Date
DK0946731T3 true DK0946731T3 (da) 2009-06-22

Family

ID=9498464

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97950245T DK0946731T3 (da) 1996-12-09 1997-12-08 Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser

Country Status (14)

Country Link
US (4) US6509018B1 (da)
EP (1) EP0946731B1 (da)
JP (1) JP2000515768A (da)
CN (1) CN1244896B (da)
AT (1) ATE422544T1 (da)
AU (1) AU737857B2 (da)
BR (1) BRPI9713891B8 (da)
CA (1) CA2274490C (da)
DE (1) DE69739251D1 (da)
DK (1) DK0946731T3 (da)
ES (1) ES2323604T3 (da)
FR (1) FR2756843B1 (da)
PT (1) PT946731E (da)
WO (1) WO1998026075A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU781934B2 (en) * 1999-07-09 2005-06-23 Gen-Probe Incorporated Detection of HIV-1 by nucleic acid amplification
DE19936003A1 (de) * 1999-08-03 2001-02-15 Dade Behring Marburg Gmbh Lentivirus aus der Gruppe der Immunschwächeviren der Drillaffen(mandrillus leucophaeus) und ihre Verwendung
CA2525640C (en) * 2003-04-11 2014-10-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
US8795685B2 (en) 2004-08-17 2014-08-05 Institut Gustave Roussy Mutated HIV Nef for modulating immunity
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2355763C2 (ru) * 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
JP2010521156A (ja) * 2007-03-16 2010-06-24 ４５４ ライフ サイエンシーズ コーポレイション Ｈｉｖ薬物耐性バリアントの検出のためのシステムおよび方法
US20090258342A1 (en) * 2008-04-09 2009-10-15 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
EP2640849B1 (en) 2010-11-16 2016-04-06 Nabsys 2.0 LLC Methods for sequencing a biomolecule by detecting relative positions of hybridized probes
WO2012109574A2 (en) 2011-02-11 2012-08-16 Nabsys, Inc. Assay methods using dna binding proteins
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
WO2014113557A1 (en) 2013-01-18 2014-07-24 Nabsys, Inc. Enhanced probe binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
EP0554389B2 (en) * 1990-10-17 2002-08-14 The United States Of America Molecular clones of hiv-1 and uses thereof
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
US5945301A (en) * 1995-09-29 1999-08-31 Chugai Seiyaku Kabushiki Kaisha Kinase in TGF-β family signal transduction system
US5994123A (en) * 1996-08-09 1999-11-30 Regents Of University Of Minnesota Sugarcane bacilliform virus promoter

Also Published As

Publication number Publication date
EP0946731A1 (fr) 1999-10-06
US8227185B2 (en) 2012-07-24
EP0946731B1 (fr) 2009-02-11
WO1998026075A1 (fr) 1998-06-18
DE69739251D1 (de) 2009-03-26
AU737857B2 (en) 2001-08-30
FR2756843A1 (fr) 1998-06-12
CN1244896A (zh) 2000-02-16
JP2000515768A (ja) 2000-11-28
US20070190524A1 (en) 2007-08-16
CA2274490C (fr) 2013-02-12
FR2756843B1 (fr) 1999-01-22
CA2274490A1 (fr) 1998-06-18
BRPI9713891B8 (pt) 2021-07-06
US7534877B2 (en) 2009-05-19
BRPI9713891A (pt) 2000-02-29
ES2323604T3 (es) 2009-07-21
US6509018B1 (en) 2003-01-21
PT946731E (pt) 2009-05-14
US20030157660A1 (en) 2003-08-21
AU5327298A (en) 1998-07-03
US20100184014A1 (en) 2010-07-22
ATE422544T1 (de) 2009-02-15
US7030234B2 (en) 2006-04-18
BRPI9713891B1 (pt) 2015-08-18
CN1244896B (zh) 2011-06-22

Similar Documents

Publication Publication Date Title
DK0946731T3 (da) Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
Wyand et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
Sawyer et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
Miyazawa et al. The genome of feline immunodeficiency virus
Krowka et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.
DE60234018D1 (de) Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
McGettigan et al. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
Callahan et al. Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene
WO2006013106A3 (en) Vaccine for prevention and treatment of hiv-infection
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
Evans et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239
Nakamura et al. Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation
ES2012129A6 (es) Un metodo para la obtencion de fragmentos de cd4 humana biologicamenteactivos.
EP0404625A3 (fr) Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
Sintasath et al. Simian T-lymphotropic virus diversity among nonhuman primates, Cameroon
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
DeVICO et al. High prevalence of serum antibodies to reverse transcriptase in HIV-1-infected individuals
SHEREFA et al. Sequence Note: Full-Length Sequence of Human Immunodeficiency Virus Type 1 Subtype A, Recombined with Subtype C in the env V3 Domain
Artenstein et al. Sequence Note: Sequences and Phylogenetic Analysis of the nef Gene from Thai Subjects Harboring Subtype E HIV-1
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.